BioSpace News Archive

Mirvie, a pioneer in predicting unexpected pregnancy complications, today announced the publication of a study in the American Journal of Obstetrics and Gynecology, a leading obstetrics and gynecology medical journal.

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), today announced that PharmaCyte has decided to accelerate preparations for the start of its Phase 2b clinical trial in locally advanced, inoperable pancreatic (LAPC) using its CypCapsTM clinical trial product.

Blue Water Vaccines Inc. announced that it has entered into definitive agreements with several institutional investors for the purchase of 1,180,812 shares of common stock in a private placement priced at-the-market under Nasdaq rules.

The American Foundation for the Blind announced the publication of the Journey Forward research report, examining the impact of the COVID-19 pandemic on U.S. adults who are blind, low vision, or deafblind.

Kleiner Device Labs today announced that its new KG2™ Surge™ flow-thru interbody system was recognized with the Bronze award in the 2022 Medical Design Excellence Awards (MDEA) in the Implant and Tissue-Replacement Products category.

Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today highlighted data being presented in collaboration with Stimunity during the American Association for Cancer Research (AACR) 2022 Annual Meeting.

Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), today announced the presentation of preclinical data and a trial in progress overview for its immunotherapy candidate NL-201, an IL-2 and IL-15 agonist, at the American Association for Cancer Research (AACR) Annual Meeting.

Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), today announced its plan to initiate a Phase I clinical trial combining CAR T cells and oncolytic virus for the treatment of recurrent glioblastoma (rGBM), supported by interim data from two ongoing investigator-sponsored Phase 1 clinical trials evaluating two clinical candidates, MB-108 (C134 oncolytic virus) and MB‐101.

Nabsys, the pioneer in electronic whole-genome mapping, announced that it has closed on $25 million in funding with strategic partner Hitachi High-Tech Corporation.

OncoNano Medicine, Inc. today announced positive results from a preclinical study of ONM-501, a novel dual-activating polyvalent STING (STimulator of INterferon Genes) agonist for immuno-oncology applications.